Artificial Intelligence-powered Drug Discovery against CTLA-4 in Cancer
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA950363 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR24017284.fastq.gz | Fastqsanger.gz | |||
| SRR24017285.fastq.gz | Fastqsanger.gz | |||
| SRR24017286.fastq.gz | Fastqsanger.gz | |||
| SRR24017287.fastq.gz | Fastqsanger.gz | |||
| SRR24017288.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 10 |
Similar Datasets
Project description:Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) plays a pivotal role in preventing autoimmunity and fostering anticancer immunity by interacting with B7 proteins CD80 and CD86. CTLA-4 is the first immune checkpoint targeted with a monoclonal antibody inhibitor. Checkpoint inhibitors have generated durable responses in many cancer patients, representing a revolutionary milestone in cancer immunotherapy. However, therapeutic efficacy is limited to a small portion of patients, and immune-related adverse events are noteworthy, especially for monoclonal antibodies directed against CTLA-4. Previously, small molecules have been developed to impair the CTLA-4: CD80 interaction; however, they directly targeted CD80 and not CTLA-4. In this study, we performed artificial intelligence (AI)-powered virtual screening of approximately ten million compounds to target CTLA-4. We validated primary hits with biochemical, biophysical, immunological, and experimental animal assays. We then optimized lead compounds and obtained inhibitors with an inhibitory concentration of 1 micromole in disrupting the interaction between CTLA-4 and CD80. Unlike ipilimumab, these small molecules did not degrade CTLA-4. Several compounds inhibited tumor development prophylactically and therapeutically in syngeneic and CTLA-4-humanized mice. This project supports an AI-based framework in designing small molecules targeting immune checkpoints for cancer therapy.
2024-02-15 | GSE228560 | GEO
Project description:Background/objectivesCheckpoint inhibitors, which generate durable responses in many cancer patients, have revolutionized cancer immunotherapy. However, their therapeutic efficacy is limited, and immune-related adverse events are severe, especially for monoclonal antibody treatment directed against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which plays a pivotal role in preventing autoimmunity and fostering anticancer immunity by interacting with the B7 proteins CD80 and CD86. Small molecules impairing the CTLA-4/CD80 interaction have been developed; however, they directly target CD80, not CTLA-4.Subjects/methodsIn this study, we performed artificial intelligence (AI)-powered virtual screening of approximately ten million compounds to identify those targeting CTLA-4. We validated the hits molecules with biochemical, biophysical, immunological, and experimental animal assays.ResultsThe primary hits obtained from the virtual screening were successfully validated in vitro and in vivo. We then optimized lead compounds and obtained inhibitors (inhibitory concentration, 1 micromole) that disrupted the CTLA-4/CD80 interaction without degrading CTLA-4.ConclusionsSeveral compounds inhibited tumor development prophylactically and therapeutically in syngeneic and CTLA-4-humanized mice. Our findings support using AI-based frameworks to design small molecules targeting immune checkpoints for cancer therapy.
| S-EPMC10838660 | biostudies-literature
Project description:We have performed paired-end RNA-sequencing on budding yeast (BY4741), exposed to 4-nitrocatechol and 3,4-Dihydroxyphenylacetic acid (DOPAC). These two human metabolites were predicted as potential carcinogens using Metabokiller, an artificial intelligence-driven carcinogenicity predictor. The dataset contains 3 biological conditions, i.e. untreated (NC), DOPAC treated (DP), and 4-nitrocatechol treated (4NC). Two rounds of selection procedures have been introduced. The first selection was for canavanine resistance, and the followed selection was for rapid cell division (inferred using growth assay). The experiment was performed in biological triplicates.
2022-06-09 | E-MTAB-11179 | biostudies-arrayexpress
Project description:Evaluation of an artificial intelligence system for polyp detection (CADe)
| 2386702 | ecrin-mdr-crc
Project description:iPAT: Platform Based on Genomics, Bioinformatics, and Artificial Intelligence to Study Pathogens Isolated in Clinical Settings.
| PRJEB96900 | ENA
Project description:During the COVID-19 pandemic, Multisystem Inflammatory Syndrome in Children (MIS-C) emerged as a disease with unknown causes and no specific diagnostic test. We used artificial intelligence in a nationwide study from April 2020 to March 2022 to identify a 4-protein diagnostic signature for MIS-C. This signature had an AUC of 1.0 for distinguishing MIS-C from other febrile diseases. Our analysis also revealed intricate protein patterns, indicating that MIS-C is associated with immune dysregulation, lipid metabolism changes, increased coagulation activity, and tissue remodeling.
2024-05-14 | PXD045661 | Pride
Project description:The application of artificial intelligence (AI) has been considered a revolutionary change in drug discovery and development. In 2020, the AlphaFold computer program predicted protein structures for the whole human genome, which has been considered a remarkable breakthrough in both AI applications and structural biology. Despite the varying confidence levels, these predicted structures could still significantly contribute to structure-based drug design of novel targets, especially the ones with no or limited structural information. In this work, we successfully applied AlphaFold to our end-to-end AI-powered drug discovery engines, including a biocomputational platform PandaOmics and a generative chemistry platform Chemistry42. A novel hit molecule against a novel target without an experimental structure was identified, starting from target selection towards hit identification, in a cost- and time-efficient manner. PandaOmics provided the protein of interest for the treatment of hepatocellular carcinoma (HCC) and Chemistry42 generated the molecules based on the structure predicted by AlphaFold, and the selected molecules were synthesized and tested in biological assays. Through this approach, we identified a small molecule hit compound for cyclin-dependent kinase 20 (CDK20) with a binding constant Kd value of 9.2 ± 0.5 μM (n = 3) within 30 days from target selection and after only synthesizing 7 compounds. Based on the available data, a second round of AI-powered compound generation was conducted and through this, a more potent hit molecule, ISM042-2-048, was discovered with an average Kd value of 566.7 ± 256.2 nM (n = 3). Compound ISM042-2-048 also showed good CDK20 inhibitory activity with an IC50 value of 33.4 ± 22.6 nM (n = 3). In addition, ISM042-2-048 demonstrated selective anti-proliferation activity in an HCC cell line with CDK20 overexpression, Huh7, with an IC50 of 208.7 ± 3.3 nM, compared to a counter screen cell line HEK293 (IC50 = 1706.7 ± 670.0 nM). This work is the first demonstration of applying AlphaFold to the hit identification process in drug discovery.
| S-EPMC9906638 | biostudies-literature
Project description:Medulloblastoma (MB) is the most common pediatric malignant central nervous system tumor. Overall survival in MB depends on treatment tuning. There is the need for biomarkers of residual disease, and recurrence. We analysed the proteome of waste cerebrospinal fluid (CSF) from extraventricular drainage (EVD) from 6 children bearing various subtypes of MB and 6 controls needing EVD insertion for unrelated causes. Samples included total CSF, Microvesicles, Exosomes, and proteins captured by combinatorial peptide ligand library (CPLL). Liquid Chromatography-Coupled Tandem Mass Spectrometry proteomics identified 3560 proteins in CSF from control and MB patients, 2412 (67.7%) of which were overlapping, and 346 (9.7%) and 805 (22.6%) exclusive. Multidimensional scaling analysis discriminated samples. The weighted gene co-expression network analysis (WGCNA) identified those modules functionally associated with the samples. A ranked core of 192 proteins allowed distinguishing between control and MB samples. Machine learning highlighted long-chain fatty acid transport protein 4 (SLC27A4), and laminin B-type (LMNB1) as proteins that maximize the discrimination between control and MB samples, respectively. Artificial intelligence was able to distinguish between MB vs non-tumor/hemorrhagic controls. The two potential protein biomarkers for the discrimination between control and MB may guide therapy and predict recurrences, improving the MB patients quality of life.
2022-10-14 | PXD035292 | Pride
Project description:Gene-gene chromatin interactions (GGIs) bring distal genes into close spatial proximity to permit strong co-expression, which could potentially contribute to cancer progression. High-throughput methods like Hi-C are impractical for very large cohort analyses, thus we developed AI4Loop, an Artificial Intelligence (AI) Deep Learning -based tool to predict GGIs using RNA-Seq data. Applying AI4Loop to 12,000 patient samples from The Cancer Genome Atlas (TCGA) database across 32 cancer types revealed that GGIs show increased cancer sub-type predictivity compared to RNA-Seq data and demonstrated oncogenic gains of GGIs in almost all cancers examined. To target the therapeutic vulnerability of gain of GGIs in cancers, using low-information RNA expression datasets from the CLUE database, we also constructed a drug-perturbation GGI atlas from 50,000 drug-treated samples to identify and repurposed compounds that disrupt oncogenic GGIs. Notably, we found that the antibiotics eperezolid and radezolid reduced cancer-acquired GGIs, which we confirmed with Hi-C experiment. This work showcases AI-directed research in epigenetics, enhances cancer biology predictivity and can promote wide-range drug repurposing in the future. This GEO submission contains the Hi-C data used to test the accuracy of AI4Loop when applied to compounds leading to loss of gene-gene interactions from the CLUE datasets.
2025-01-21 | GSE287383 | GEO
Project description:A high-resolution, nanopore-based artificial intelligence assay for DNA replication stress in human cancer cells.
| PRJEB80561 | ENA